165 results
8-K
EX-99.1
RGTPQ
Polarityte, Inc.
11 Aug 22
PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update
4:06pm
clinical trial. The Company believes this strategy will be the fastest and least costly approach to achieving its first BLA submission for SkinTE
424B3
RGTPQ
Polarityte, Inc.
1 Jul 22
Prospectus supplement
8:30am
and plans for expediting the manufacturing development strategy.
We expect to incur significant operating costs in the next three to four years as we
424B5
xhlf6cgs
7 Jun 22
Prospectus supplement for primary offering
4:30pm
8-K
EX-99.1
1suprcwm
16 May 22
PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
7:30am
8-K
EX-99.1
3ilybbl1c07mnq xq
13 May 22
Regulation FD Disclosure
8:00am
8-K
ncs5tk3mjr
18 Apr 22
Entry into a Material Definitive Agreement
8:00am
424B3
69j qxddw8uq2l2
17 Mar 22
Prospectus supplement
4:45pm
424B3
52lfkkgfk5jsv5fq
17 Mar 22
Prospectus supplement
4:45pm
8-K
jkfqijgge t2z8s59m8
15 Mar 22
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
fs6y06543sndwozcc
18 Jan 22
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to
8:00am
8-K
lr8ul8n
23 Dec 21
Departure of Directors or Certain Officers
4:30pm
8-K
0vkawoxp
17 Dec 21
Entry into a Material Definitive Agreement
5:00pm